Abstract
The emergence of the novel coronavirus SARS-CoV-2 has resulted in a worldwide pandemic not seen in generations. Creating treatments and vaccines to battle COVID-19, the disease caused by the virus, is of paramount importance in order to stop its spread and save lives. The viral main protease, 3CL Mpro, is indispensable for the replication of SARS-CoV-2 and is therefore an important target for the design of specific protease inhibitors. Detailed knowledge of the structure and function of 3CL Mpro is crucial to guide structure-aided and computational drug-design efforts. Here, the oxidation and reactivity of the cysteine residues of the protease are reported using room-temperature X-ray crystallography, revealing that the catalytic Cys145 can be trapped in the peroxysulfenic acid oxidation state at physiological pH, while the other surface cysteines remain reduced. Only Cys145 and Cys156 react with the alkylating agent N-ethylmaleimide. It is suggested that the zwitterionic Cys145-His45 catalytic dyad is the reactive species that initiates catalysis, rather than Cys145-to-His41 proton transfer via the general acid-base mechanism upon substrate binding. The structures also provide insight into the design of improved 3CL Mpro inhibitors.
Original language | English |
---|---|
Pages (from-to) | 1028-1035 |
Number of pages | 8 |
Journal | IUCrJ |
Volume | 7 |
DOIs | |
State | Published - Nov 1 2020 |
Funding
This research used resources at the Spallation Neutron Source and the High Flux Isotope Reactor, which are DOE Office of Science User Facilities operated by Oak Ridge National Laboratory (ORNL). The Office of Biological and Environmental Research supported research at ORNL’s Center for Structural Molecular Biology (CSMB), a DOE Office of Science User Facility. The authors declare no conflicts of interest. This research was supported by the DOE Office of Science through the National Virtual Biotechnology Laboratory (NVBL), a consortium of DOE national laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act. Funding for this project was provided in part by federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under Contract No. HHSN272201700060C and by the US Department of Energy (DOE) Office of Science, operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.
Funders | Funder number |
---|---|
National Virtual Biotechnology Laboratory | |
ORNL’s Center for Structural Molecular Biology | |
Office of Biological and Environmental Research | |
US Department of Energy | |
National Institutes of Health | |
U.S. Department of Energy | |
U.S. Department of Health and Human Services | HHSN272201700060C |
National Institute of Allergy and Infectious Diseases | |
Office of Science | |
Argonne National Laboratory | DE-AC02-06CH11357 |
Canadian Society for Molecular Biosciences |
Keywords
- 3CL M
- 3CL main protease
- SARS-CoV-2
- cysteine oxidation
- drug design
- enzyme mechanism
- protonation state
- room-temperature X-ray crystallography